鹿角壮督汤治疗强直性脊柱炎的临床观察
Clinical observation of Lujiao Zhuangdu Decoction in treating ankylosing spondylitis
- 上海中医药大学学报 2023年37卷第3期 页码：30-34
- 作者机构：
1.上海中医药大学附属市中医医院风湿病科（上海 200071）
- 作者简介：
张娜，女，博士，主治医师，主要从事中医药治疗风湿免疫性疾病临床研究
陈薇薇，主任医师，硕士生导师；E-mail：daphneww@126.com
- 基金信息：上海市卫健委名老中医学术经验研究工作室建设项目(ZYSNXD-CC-MZY048);上海市中医医院未来计划项目(WLJH2021ZY-MZY037)
DOI：10.16306/j.1008-861x.2023.03.006
中图分类号：
扫 描 看 全 文
张娜,沈丕安,陈薇薇.鹿角壮督汤治疗强直性脊柱炎的临床观察[J].上海中医药大学学报,2023,37(03):30-34.
ZHANG Na,SHEN Pi’an,CHEN Weiwei.Clinical observation of Lujiao Zhuangdu Decoction in treating ankylosing spondylitis[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):30-34.
张娜,沈丕安,陈薇薇.鹿角壮督汤治疗强直性脊柱炎的临床观察[J].上海中医药大学学报,2023,37(03):30-34. DOI： 10.16306/j.1008-861x.2023.03.006.
ZHANG Na,SHEN Pi’an,CHEN Weiwei.Clinical observation of Lujiao Zhuangdu Decoction in treating ankylosing spondylitis[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):30-34. DOI： 10.16306/j.1008-861x.2023.03.006.
摘要
目的,2,观察自拟鹿角壮督汤对强直性脊柱炎（AS）炎性因子影响及临床疗效。,方法,2,将80例AS患者随机分为对照组和治疗组，每组40例。对照组给予塞来昔布胶囊口服，治疗组在对照组治疗基础上加用鹿角壮督汤，疗程12周。疗程结束后，观察两组患者的临床疗效及治疗前后血清学炎性指标C反应蛋白（CRP）、红细胞沉降率（ESR）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α），强直脊柱炎功能指数（BASFI）、强直脊柱炎疾病活动指数（BASDAI）、强直性脊柱炎计量学指数（BASMI），强直性脊柱炎疾病活动评分（ASDAS），脊柱活动度（Schober）试验、指地距、枕墙距、胸廓扩张度测量值变化情况。,结果,2,①最终完成试验治疗组40例，对照组39例。②治疗组总有效率90.00%，对照组总有效率84.62%；两组临床疗效比较，差异有统计学意义（,P,<,0.05）。③治疗后，两组CRP、ESR、IL-6、TNF-α较治疗前降低（,P,<,0.05）；组间治疗后比较，治疗组CRP、ESR、IL-6、TNF-α较对照组明显降低（,P,<,0.05）。④治疗后，两组BASFI、BASDAI、BASMI评分均较治疗前降低（,P,<,0.05）；组间治疗后比较，治疗组BASFI、BASDAI、BASMI评分较对照组明显降低（,P,<,0.05）。⑤治疗后，两组ASDAS-CRP、ASDAS-ESR评分均较治疗前降低（,P,<,0.05）；组间治疗后比较，治疗组ASDAS-CRP、ASDAS-ESR评分较对照组明显降低（,P,<,0.05）；⑥治疗后，两组Schober试验测量值较治疗前增加、指地距降低（,P,<,0.05）；组间治疗后比较，治疗组Schober试验测量值、指地距均优于对照组（,P,<,0.05）；枕墙距及胸廓扩张度组内及组间比较均未见明显改善（,P,>,0.05）。,结论,2,鹿角壮督汤能够有效下调AS患者炎症因子水平，降低BASFI、BASDAI、BASMI、ASDAS-CRP、ASDAS-ESR评分，改善Schober试验及指地距离，疗效显著，安全可靠。
Abstract
Objective： To observe the effect of Lujiao Zhuangdu Decoction on inflammatory factors of ankylosing spondylitis （AS） and its clinical efficacy.,Methods,2,A total of 80 AS patients were randomly divided into the control group and the treatment group，40 cases in each group. The control group was given oral celecoxib capsules， and the treatment group was given Lujiao Zhuangdu Decoction on the basis of the control group， and the course of treatment was 12 weeks. After the course of treatment， the clinical efficacy of the two groups and the levels of serum inflammatory indexes CRP，ESR，IL-6，TNF-α，ankylosing spondylitis functional index（BASFI），ankylosing spondylitis disease activity index（BASDAI），ankylosing spondylitis metrology index（BASMI）， ankylosing spondylitis disease activity score（ASDAS），spinal range of motion （Schober） test，finger-to-ground distance，pillow-to-wall distance，and changes in thoracic expansion measurements were observed.,Results,2,①Finally，40 cases in the experimental treatment group and 39 cases in the control group were completed.②The total effective rate in the treatment group was 90.00%，and the total effective rate in the control group was 84.62%； the difference in clinical efficacy between the two groups was statistically significant （,P,<,0.05）.③After treatment， the CRP，ESR，IL-6 and TNF-α in the two groups were lower than those before treatment（,P,<,0.05）.Compared with the two groups after treatment，CRP，ESR，IL-6 and TNF-α in the treatment group were significantly lower than those in the control group （,P,<,0.05）.④After treatment， the BASFI，BASDAI， and BASMI scores of the two groups were all lower than those before treatment（,P,<,0.05）. Compared with the two groups after treatment， the BASFI，BASDAI， and BASMI scores in the treatment group were significantly lower than those in the control group （,P,<,0.05）.⑤After treatment， the scores of ASDAS-CRP and ASDAS-ESR in the two groups were decreased compared with those before treatment（,P,<,0.05）.Compared with the two groups after treatment， the scores of ASDAS-CRP and ASDAS-ESR in the treatment group were significantly lower than those in the control group（,P,<,0.05）.⑥After treatment， the measured values of Schober’s test in the two groups were increased and the finger-to-ground distance were decreased compared with those before treatment （,P,<,0.05）.Compared with the two groups after treatment， the measured values of Schober’s test and finger-to-ground distance in the treatment group were better than those in the control group （,P,<,0.05）；pillow-wall distance and thoracic expansion were not significantly improved within or between groups（,P,>,0.05）.,Conclusion,2,Lujiao Zhuangdu Decoction can effectively down-regulate the level of inflammatory factors in AS patients， reduce BASFI，BASDAI，BASMI，ASDAS-CRP，ASDAS-ESR scores， and improve Schober test and finger-to-ground distance with significant curative effect and safety.
关键词
鹿角壮督汤强直性脊柱炎炎症因子病情活动度临床疗效
Keywords
Lujiao Zhuangdu Decoctionankylosing spondylitisinflammatory factorsdisease activityclinical efficacy
references
韩曼，姜泉. 路志正治疗强直性脊柱炎经验［J］. 中医杂志，2016， 57（19）： 1634-1636.
HAN M， JIANG Q. LU Zhizheng’s experience in treating ankylosing spondylitis［J］. Journal of Traditional Chinese Medicine， 2016， 57（19）： 1634-1636.
中华医学会风湿病学分会. 强直性脊柱炎诊断及治疗指南［J］. 中华风湿病学杂志，2010， 14（8）： 357-359.
Rheumatology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of ankylosing spondylitis［J］. Chinese Journal of Rheumatology， 2010，14（8）：357-359.
徐然，纪伟. 强直性脊柱炎中医证型研究进展［J］. 辽宁中医药大学学报，2020，22（2）：161-164.
XU R， JI W. Advances in research on tcm syndromes of ankylosing spondylitis［J］. Journal of Liaoning University of Traditional Chinese Medicine， 2020， 22（2）： 161-164.
HUANG S Q，LI H L，XIONG J， et al. The effectiveness of Du moxibustion for ankylosing spondylitis： A protocol for systematic review and meta-analysis of randomized clinical trials［J］. Medicine （Baltimore）， 2020， 99（31）： e21450.
丁繁荣，姜萍，刘巍. 强直性脊柱炎中医诊疗进展［J］. 山东中医杂志，2019，38（8）： 805-808.
DING F R， JIANG P， LIU W. Progress on TCM diagnosis and treatment of ankylosing spondylitis［J］. Shandong Journal of Traditional Chinese Medicine， 2019， 38（8）： 805-808.
VAN DER L S，VALKENBURG H A， CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis：A proposal for modification of the New York criteria［J］. Arthritis Rheum，1984， 27（4）： 361-368.
国家药品监督管理局. 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002： 119-123.
National Medical Products Administration. Guidelines for clinical research of new Chinese medicine （Trial） ［M］. Beijing： China Medical Science and Technology Press， 2002： 119-123.
沈丕安. 风湿病免疫病学术思想与临床［M］. 上海：上海世纪出版集团上海辞书出版社，2018： 628-629.
SHEN P A. Academic thought and clinic of rheumatic immunology［M］. Shanghai： Shanghai Century Publishing Company Shanghai Dictionary Publishing House， 2018： 628-629.
徐静雯，何文姬，胡燕琪，等. 名老中医沈丕安补肾壮督法辨治强直性脊柱炎经验［J］. 现代中西医结合杂志，2020， 29（7）：736-739.
XU J W， HE W J， HU Y Q， et al. Experience of famous Chinese doctor Shen Pi’an in treating ankylosing spondylitis by invigorating kidney and strengthening governor channel method［J］. Journal of Modern Integrated Chinese and Western Medicine， 2020， 29（7）： 736-739.
张成亮，朱宝林，吴建伟. 探讨HLA-B27阳性率、TNF-α、CRP水平检测对强直性脊柱炎的诊断价值［J］. 检验医学与临床，2018， 15（7）： 999-1001.
ZHANG C L， ZHU B L， WU J W. Exploring the diagnostic value of HLA-B27 positive rate， TNF-α and CRP levels in ankylosing spondylitis［J］. Laboratory medicine and clinic， 2018， 15（7）： 999-1001.
LI X L， LIN T T， QI C Y， et al. Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis： associated with disease activity and vascular endothelial growth factor［J］. Investing Med， 2013， 61（5）： 848-851.
LIU Z， GAO L， WANG P， et al. TNF-α induced the enhanced apoptosis of mesenchymal stem cells in ankylosing spondylitis by overexpressing TRAIL-R2［J］. Stem Cells Int， 2017（10）： 1-14.
GRACEY E，YAO Y，GREEN B， et al. Sexual dimorphism in the Th17 signature of ankylosing spondylitis［J］. Arthritis Rheumatol， 2016， 68（3）： 679-689.
SARI S， BAYLAN B，SEZER E， et al. Percutaneous nephrolithotomy performed on the kidney stone in a patient with ankylosing spondylitis： a case study［J］. Urol Case Rep， 2015， 3（4）： 123-125.
石柳. 强直性脊柱炎患者血清TNF-α和IL-6水平变化及意义［D］. 广州：南方医科大学， 2019.
SHI L. Changes of serum TNF-α and IL-6 levels in patients with ankylosing spondylitis and their significance［D］.Guangzhou： Southern Medical University， 2019.
张成亮，朱宝林，吴建伟，等. 强直性脊柱炎患者治疗前后免疫功能与细胞因子的变化及意义［J］. 检验医学与临床，2018，（15）15：2336-2338.
ZHANG C L， ZHU B L， WU J W， et al. Changes of immune function and cytokines in patients with ankylosing spondylitis before and after treatment and their significance［J］. Laboratory Medicine and Clinic，2018， （15）15： 2336-2338.
LI L， CHEN B， ZHAO H， et al. Bone changes and curative effect of infliximab in patients with ankylosing spondylitis［J］. J Musculoskelet Neuronal Interact， 2020， 20（3）： 437-443.
陈焕亮，祁冀. 炎性相关因子与强直性脊柱炎患者的脊柱活动度的相关性分析［J］. 中国中医骨伤科杂志， 2016， 24（11）：57-58.
CHEN H L， QI J. Correlation analysis of Inflammatory factors with spinal range of motion in ankylosing spondylitis patients［J］. Chinese Journal of Traditional Medical Traumatology & Orthopedics， 2016， 24（11）： 57-58.
LUKAS C， LANDEWÉ R， SIEPER J， et al. Development of an ASAS-endorsed disease activity score （ASDAS） in patients with ankylosing spondylitis［J］. Ann Rheum Dis， 2009， 68（1）： 18-24.
MACHADO P， LANDEWÉ R， LIE E， et al. Ankylosing Spondylitis Disease Activity Score （ASDAS）： defining cut-off values for disease activity states and improvement scores［J］. Ann Rheum Dis， 2011， 70（1）： 47-53.
徐胜前，黄烽. 强直性脊柱炎的达标治疗［J］. 中华内科杂志，2014， 53（11）： 841-843.
XU S Q， HUANG F. Standard treatment of ankylosing spondylitis［J］. Chinese Journal of Internal Medicine， 2011， 70（1）： 47-53.
SOFIA R， DÉSIRÉE V D H， ASTRID V T， et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis：12-year longitudinal data from the OASIS cohort［J］. Ann Rheum Dis， 2014， 73（8）： 1455-1461.
沈丕安. 中药药理与临床运用［M］. 长春：吉林科学技术出版社，2019： 67-101.
SHEN P A. Pharmacology and clinical application of Chinese medicine［M］. Changchun： Jilin Science and Technology Press， 2019： 67-101.
0
浏览量
40
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：10154 今日访问量：17